Chinook is a clinical-stage biopharmaceutical company discovering, developing and commercializing precision medicines for rare, severe chronic kidney diseases.

Chronic kidney diseases are a severe and growing worldwide problem with a lack of effective treatments often leading to dialysis, transplantation, and high costs to health care systems. In the U.S. alone, kidney diseases affect an estimated 37 million people and account for over $120 billion in annual costs.

Drug development in kidney diseases is experiencing a resurgence due to greater understanding of disease biology, utilization of novel translational platforms and patient stratification tools, and emergence of accelerated regulatory pathways based on surrogate endpoints. These dynamics have converged to create attractive opportunities for the development of precision therapies.

At Chinook, we are focused on rare, severe chronic kidney diseases with well-defined clinical pathways. Our lead clinical program, atrasentan, is an endothelin receptor antagonist that was in-licensed from AbbVie in 2019. We plan to initiate a phase 3 trial (ALIGN) of atrasentan for IgA Nephropathy in early 2021, as well as a phase 2 basket trial (AFFINITY) for primary glomerular diseases during the first half of 2021. BION-1301, an investigational anti-APRIL monoclonal antibody, is being evaluated in a Phase 1b trial for IgA Nephropathy. We are also advancing an internal program, CHK-336, for the treatment of Primary Hyperoxaluria towards a planned IND submission in 2021. In addition, we are conducting research programs in polycystic kidney disease and other rare, severe chronic kidney diseases. We seek to build our pipeline by leveraging insights in single cell RNA sequencing of patient kidney samples, human-derived organoids and new translational models in order to discover and develop therapeutics with mechanisms of action targeted against key kidney disease pathways.

Our Purpose & Values

We discover and develop precision therapies to preserve kidney function and make dialysis and transplant unnecessary for people living with kidney disease.

 

Chinook Values graphic

Leadership

Eric Dobmeier photo

Eric Dobmeier
President and Chief Executive Officer

Tom Frohlich photo

Tom Frohlich
Chief Business Officer

Alan Glicklich photo

Alan Glicklich, MD
Chief Medical Officer

Kirk Shumacher photo

Kirk Schumacher, JD
SVP AND GENERAL COUNSEL

Andrew King photo

Andrew King, DVM, PhD
Head of Renal Discovery and Translational Medicine

Renata Oballa photo

Renata Oballa, PhD
VP, CHEMISTRY AND VANCOUVER SITE HEAD

Jodi Jamieson photo

Jodi Jamieson
VP, Human Resources

Board of Directors

Eric Dobmeier
CEO, Chinook Therapeutics

Srini Akkaraju
Managing GP, Samsara Biocapital

Jerel Davis
Managing Director, Versant

Ross Haghighat
CEO, Triton Systems, Inc.

William M. Greenman
CEO, Cerus Corporation

Michelle Griffin
Independent Director

Dolca Thomas
CMO, Principia Biopharma